AMENDMENTS TO THE CLAIMS:

The following is a complete listing of the claims and reflects all changes currently being made to the claims. This listing supersedes all earlier versions and all earlier listings of the claims.

1. (Previously Presented) A solid pharmaceutical dosage form comprising caffeine, a disintegrant selected from the group consisting of sodium starch glycolate, crosslinked carboxymethylcellulose, and mixtures thereof, and a cephalagic, wherein said caffeine is in the form of uncoated ungranulated particles having a granular morphology and an average particle size of about 70 to 600 microns, and wherein at least 86 % of said caffeine dissolves within 5 minutes, when measured by USP, Type II Apparatus (Paddles) set at 50 rpm.

2. (Previously Presented) The dosage form of claim 1, wherein the cephalagic is selected from analgesics, non-steroidal anti-inflammatory drugs, decongestants, and antihistamines.

3. (Previously Presented) The dosage form of claim 1, wherein the cephalagic is selected from the group consisting of acetaminophen, ibuprofen, ketoprofen, chlorpheniramine, diphenhydramine, and doxcylamine.

4. (Previously Presented) The dosage form of claim 1, wherein the cephalagic is in the form of a granulation.

5. (Previously Presented) The dosage form of claim 4, wherein the granulation has an average particle size of about 100 to 400 microns.

6. (Previously Presented) The dosage form of claim 1 in the form of a directly compressed tablet.

7. CANCELLED.

8. (Withdrawn) A process for making a solid, pharmaceutical dosage form, which comprises dry blending caffeine and a cephalagic into a blend, wherein said caffeine is in the form of uncoated particles having an average particle size of about 70 to 600 microns, and compressing the blend.

9. (Withdrawn) The process of claim 8, wherein the cephalagic is selected from the group consisting of acetaminophen, ibuprofen, ketoprofen, chlorpheniramine, diphenhydramine, and doxcylamine.

10. (Withdrawn) The process of claim 8, wherein the cephalagic is in the form of a granulation.

11. (Withdrawn) The process of claim 10, wherein the granulation has an average particle size of about 100 to 400 microns.

12. (Withdrawn) The process of claim 8, wherein at least 95 % of the caffeine in the compressed blend dissolves within 5 minutes, when measured by USP, Type II Apparatus (Paddles) set at 50 rpm.

13. (Withdrawn) A compressed tablet made by the process of claim 8.

14. (Previously Presented) The solid pharmaceutical dosage form of Claim 1, wherein at least 95 % of said caffeine dissolves within 5 minutes, when measured by USP, Type II Apparatus (Paddles) set at 50 rpm.

15. (New) A solid pharmaceutical dosage form comprising:

about 5 mg to about 400 mg of caffeine,

a disintegrant selected from the group consisting of sodium starch glycolate, crosslinked carboxymethylcellulose, and mixtures thereof, and

a cephalagic,

wherein said caffeine is in the form of uncoated ungranulated particles having a granular morphology and an average particle size of about 70 to 600 microns, and wherein at least 86 % of said caffeine dissolves within 5 minutes, when measured by USP, Type II Apparatus (Paddles) set at 50 rpm.